GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Change In Receivables

BerGenBio ASA (OSL:BGBIO) Change In Receivables : kr-5.34 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Change In Receivables?

BerGenBio ASA's change in receivables for the quarter that ended in Mar. 2024 was kr-0.44 Mil. It means BerGenBio ASA's Accounts Receivable increased by kr0.44 Mil from Dec. 2023 to Mar. 2024 .

BerGenBio ASA's change in receivables for the fiscal year that ended in Dec. 2023 was kr-1.62 Mil. It means BerGenBio ASA's Accounts Receivable increased by kr1.62 Mil from Dec. 2022 to Dec. 2023 .

BerGenBio ASA's Accounts Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BerGenBio ASA's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BerGenBio ASA's liquidation value for the three months ended in Mar. 2024 was kr75.24 Mil.


BerGenBio ASA Change In Receivables Historical Data

The historical data trend for BerGenBio ASA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Change In Receivables Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only 2.01 1.59 1.83 -3.46 -1.62

BerGenBio ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 -1.85 -3.71 0.67 -0.44

BerGenBio ASA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BerGenBio ASA  (OSL:BGBIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BerGenBio ASA's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.167*91
=0.00

2. In Ben Graham's calculation of liquidation value, BerGenBio ASA's accounts receivable are only considered to be worth 75% of book value:

BerGenBio ASA's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=117.348-42.113+0.75 * 0+0.5 * 0
=75.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BerGenBio ASA Change In Receivables Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA (OSL:BGBIO) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines